Diffusion tensor imaging and behavior in premature infants at 8 years of age, a randomized controlled trial with long-chain polyunsaturated fatty acids

Early Hum Dev. 2016 Apr:95:41-6. doi: 10.1016/j.earlhumdev.2016.01.021. Epub 2016 Mar 2.

Abstract

Background: Very low birth weight (VLBW, birth weight<1500 g) children have increased risk of behavioral problems. Diffusion tensor imaging (DTI) of the brain shows reduced white matter maturation. Long-chain polyunsaturated fatty acids are hypothesized to improve both myelination and behavioral outcome.

Aims: To test the hypothesis that postnatal supplementation with docosahexaenoic acid (DHA) and arachidonic acid (AA) to very low birth weight infants would influence cerebral white matter measured by DTI and improve behavioral outcome at 8 years of age.

Study design: Eight-year follow-up of a randomized, double-blinded, placebo-controlled study of postnatal supplementation with DHA and AA to 129 VLBW infants fed human milk.

Subjects: Ninety-eight children (76%) met for follow-up at 8 years.

Outcome measures: Cerebral white matter measured by DTI. Behavioral outcome measured by Strengths and Difficulties questionnaire and selected scales from the Child Behavior Checklist.

Results: No significant differences between the intervention group and the control group were found on white matter microstructure or behavioral data. A non-significant finding of higher fractional anisotropy (FA) in a cluster in the corpus callosum of the intervention group is discussed.

Conclusions: The present study is the first long-term follow-up of a randomized controlled trial with DHA and AA to human milk fed VLBW infants exploring cerebral white matter microstructure measured by DTI and parent-reported behavioral problems. No effects on white matter microstructure or behavioral outcome were observed at 8 years of age.

Trial registration: ClinicalTrials.gov NCT00226187.

Keywords: Behavioral outcome; Brain development; Diffusion tensor imaging; Long-chain polyunsaturated fatty acids; Premature children; White matter maturation.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arachidonic Acid / administration & dosage
  • Arachidonic Acid / pharmacology
  • Arachidonic Acid / therapeutic use
  • Child Behavior Disorders / drug therapy
  • Child Behavior Disorders / prevention & control*
  • Child Development / drug effects*
  • Dietary Supplements
  • Diffusion Tensor Imaging
  • Docosahexaenoic Acids / administration & dosage
  • Docosahexaenoic Acids / pharmacology
  • Docosahexaenoic Acids / therapeutic use*
  • Female
  • Humans
  • Infant, Newborn
  • Infant, Very Low Birth Weight / growth & development*
  • Male
  • White Matter / drug effects
  • White Matter / pathology

Substances

  • Docosahexaenoic Acids
  • Arachidonic Acid

Associated data

  • ClinicalTrials.gov/NCT00226187